Helen Philippou

Helen Philippou

Auto-generated profile, based on publicly available information

Helen Philippou

Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 3AA, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2005 in Blood
Verified
Journal Article
Closed access
PDF file
DLDavid A. Lane
David A. Lane
HPHelen Philippou
Helen Philippou
JHJames A. Huntington
James A. Huntington
Following initiation of coagulation as part of the hemostatic response to injury, thrombin is generated from its inactive precursor prothrombin by factor Xa as part of the prothrombinase complex. Thrombin then has multiple roles. The way in which thrombin interacts with its many substrates has been carefully scrutinized in the past decades, but until recently there has been little consideration of how its many functions are coordinated or directed. Any understanding of how it is directed requires knowledge of its structure, how it interacts with its substrates, and the role of any cofactors for its interaction with substrates. Recently, many of the interactions of thrombin have been clarified by crystal structure and site-directed mutagenesis analyses. These analyses have revealed common residues used for recognition of some substrates and overlapping surface exosites used for recognition by cofactors. As many of its downstream reactions are cofactor driven, competition between cofactors for exosites must be a dominant mechanism that determines the fate of thrombin. This review draws together much recent work that has helped clarify structure function relationships of thrombin. It then attempts to provide a cogent proposal to explain how thrombin activity is directed during the hemostatic response.

1 June 1997 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
GLG. D. O. Lowe
G. D. O. Lowe
ARA. Rumley
A. Rumley
MWM. Woodward
M. Woodward
CMC. E. Morrison
C. E. Morrison
HPH. Philippou
H. Philippou
HTH. Tunstall‐Pedoe
H. Tunstall‐Pedoe

21 November 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
EHE. L. Hethershaw
E. L. Hethershaw
ACA. L. Cilia La Corte
A. L. Cilia La Corte
CDCedric Duval
Cedric Duval
MAM. Ali
M. Ali
PGP. J. Grant
P. J. Grant
HPH. Philippou
H. Philippou
Background Factor XIII is a 320 kDa tetramer, comprising two enzymatic A‐subunits and two carrier B‐subunits (FXIII A2B2). Activated FXIII (FXIIIa) catalyses the formation of ε‐(γ‐glutamyl)lysyl covalent bonds between γ‐γ, γ‐α and α‐α chains of adjacent fibrin molecules and also cross‐links the major plasmin inhibitor, α2‐antiplasmin, to fibrin. Objectives We investigated the role of FXIII cross‐linking of fibrin directly in clot morphology and its functional effect on clot formation and lysis, in the absence of α2‐antiplasmin. Results and Conclusions Our data show that the presence of FXIII during clot formation results in fibrin clots that have a significant 2.1‐fold reduction in pore size, as determined by the Darcy constant, Ks, and formed thinner fibers (74.7 ± 1.5 nm) and higher density of fibers compared with those without FXIII (86.0 ± 1.7 nm, P < 0.001), as determined by scanning electron microscopy. Additionally, fibrinolysis showed a significant increase in the time to lysis for clots formed in the presence of FXIII in both static and flow systems. These data demonstrate that independent of α2‐antiplasmin, FXIII activity plays a role in increasing the stability of the fibrin clot by altering its structure and increasing the resistance to fibrinolysis.

16 March 2006 in Diabetologia
Verified
Journal Article
Closed access
PDF file
EDE. J. Dunn
E. J. Dunn
HPH. Philippou
H. Philippou
RARobert A.S. Ariens
Robert A.S. Ariens
PGP. J. Grant
P. J. Grant

13 May 2010 in Blood
Verified
Journal Article
Closed access
PDF file
NMNicola J Mutch
Nicola J Mutch
RERuchira Engel
Ruchira Engel
SWShirley Uitte de Willige
Shirley Uitte de Willige
HPHelen Philippou
Helen Philippou
RARobert A.S. Ariens
Robert A.S. Ariens
Activated platelets secrete a negatively charged polymer, polyphosphate (polyP). Here, we explore the interactions of polyP with fibrin(ogen) and its effect on fibrin structure and fibrinolysis. Electrophoretic mobility and binding assays indicate that polyP interacts with fibrinogen and soluble fibrin. Clots formed in the presence of polyP exhibited reduced turbidity and permeability indicative of a tighter fibrin network, but these changes were not related to cross-linking or fibrinopeptide release. Microscopy showed a change in fibrin distribution in clots formed with polyP; with formation of tight aggregates of fibrin fibers interspaced with large pores in contrast to homogenous fiber distribution in control clots. Lysis by tissue plasminogen activator (tPA) and plasminogen or plasmin was delayed in clots formed with polyP and depended on both the activator and polyP concentration. Adding polyP to the clot after fibrin formation or to repolymerizing soluble fibrin did not affect lysis, indicating changes induced by polyP occur at the level of conversion of fibrinogen to fibrin. Surface plasmon resonance showed that the presence of polyP reduced the binding of both plasminogen and tPA to partially lysed fibrin surfaces. These data show that polyP directly influences fibrin architecture and attenuates fibrinolysis through reduced binding of fibrinolytic proteins.

22 February 2018 in Haematologica
Verified
Journal Article
Open access
PDF file
PMPierre H Mangin
Pierre H Mangin
MOMarie-Blanche Onselaer
Marie-Blanche Onselaer
NRNicolas Receveur
Nicolas Receveur
NLNicolas Le Lay
Nicolas Le Lay
AHAlexander T Hardy
Alexander T Hardy
SWStephen P. Watson
Stephen P. Watson
GPVI, a major platelet activation receptor for collagen and fibrin, is considered as a particularly promising safe antithrombotic target. In this study, we show that human GPVI signals upon platelet adhesion to fibrinogen. Full spreading of human platelets on fibrinogen is abolished in platelets from GPVI-deficient patients suggesting that fibrinogen activates platelets through GPVI. While mouse platelets fail to spread on fibrinogen, human-GPVI-transgenic mouse platelets show full spreading and increased Ca2+ signalling through the tyrosine kinase Syk. Direct binding of fibrinogen to human GPVI was shown by surface plasmon resonance and by increased adhesion of human GPVI-transfected Rbl-2H3 cells to fibrinogen relative to mock-transfected cells. Blockade of human GPVI with the Fab of the monoclonal antibody 9O12 impairs platelet aggregation on preformed platelet aggregates in flowing blood independent of collagen and fibrin exposure. These results demonstrate that human GPVI binds to immobilized fibrinogen and show that this contributes to platelet spreading and platelet aggregation under flow.